Document is current
Any future updates will be listed below
-
Authors
López, Noelia https://orcid.org/0000-0001-8568-4752
de la Cueva, Ignacio Salamanca
Taborga, Elena
de Alba, Auxiliadora Fernández
Cabeza, Inés
Raba, Reyes Mazas
Marès, Josep
Company, Patricia
Herrera, Bruno
Cotarelo, Manuel
-
Funding
Funding for this research was provided by:
MSD Spain
- License Information
-
More Information
Article History
Received: 7 October 2021
Accepted: 31 October 2022
First Online: 17 November 2022
Declarations
:
: The study was approved by the Comité de Ética de la investigación con medicamentos de Euskadi (CEIm-E) reference ethics committee on 08th January, 2019.Acceptance to participate was obtained from all subjects involved in the study.
: Not applicable.
: NL, BH, and MC are full-time employee of MSD Spain. ISdlC has received grants and/or honoraria as a consultant/advisor or attending conferences and practical courses from GlaxoSmithKline, Sanofi Pasteur, MSD and Pfizer. ET has received honoraria from MSD as an investigator for this study. AFdA has received honoraria from MSD as an investigator for this study. IC has received honoraria from MSD as an investigator for this study and grants for medical education activities. She has also participated as speaker for other pharmaceutical companies. RMR has received honoraria from MSD as investigator for this study. JM has received grants from MSD as an investigator for this study and payments for lectures including service on speaker bureau and as a board membership from GlaxoSmithKline, Sanofi Pasteur, MSD and Pfizer. PC has received honoraria from MSD as investigator for this study.
